{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreieesmvzhfpm2wchkjvyzh37tfxatc2q5yvzttrxdmexfu2gk6obye",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mlojwb5payc2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiaxolq3ibyftylrfwh74tgrg3sn2potuvls3urhjl4fmu6wv5u53a"
    },
    "mimeType": "image/jpeg",
    "size": 118183
  },
  "path": "/news/2026-05-fda-arteraai-breast-cancer-stratification.html",
  "publishedAt": "2026-05-12T15:00:07.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "The U.S. Food and Drug Administration has cleared ArteraAI Breast for use in patients with early-stage, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative invasive breast cancer.",
  "title": "FDA clears ArteraAI Breast for breast cancer risk stratification"
}